Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | TTK | P33981 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27737402 | 0.87 | CA12 (0.63) | NCF1AURKATTKAURKBINCENP | |
| SCHEMBL12074333 | 0.85 | PIK3CA (0.65) | NCF1AURKATTKAURKBINCENP | |
| SCHEMBL30439957 | 0.84 | TGFBR1 (0.60) | NCF1AURKATTKAURKBINCENP | |
| SCHEMBL35327 | 0.84 | TGFBR1 (0.60) | NCF1AURKATTKAURKBINCENP | |
| SCHEMBL17945617 | 0.82 | CYP1A2 (0.57) | NCF1AURKATTKAURKBINCENP | |
| SCHEMBL12580359 | 0.82 | PIK3CA (0.54) | AURKATTKAURKBINCENPACVR1 | |
| SCHEMBL12580413 | 0.82 | PIK3CA (0.54) | AURKATTKAURKBINCENPACVR1 | |
| SCHEMBL18805529 | 0.81 | GRM4 (0.62) | NCF1AURKATTKAURKBINCENP | |
| SCHEMBL19219069 | 0.81 | PIK3CA (0.71) | NCF1AURKATTKAURKBINCENP | |
| SCHEMBL3974245 | 0.81 | ACVR1 (0.50) | NCF1AURKATTKAURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259800-B2 | Method of fluorination using iodonium ylides | THE GENERAL HOSPITAL CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| US-10259800-B2 | Method of fluorination using iodonium ylides | THE GENERAL HOSPITAL CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| EP-3240057-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | Hodogaya Chemical Co., Ltd. (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-20170121300-A1 | METHOD OF FLUORINATION USING IODONIUM YLIDES | THE GENERAL HOSPITAL CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-20170121300-A1 | METHOD OF FLUORINATION USING IODONIUM YLIDES | THE GENERAL HOSPITAL CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-20170121300-A1 | METHOD OF FLUORINATION USING IODONIUM YLIDES | THE GENERAL HOSPITAL CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| WO-2003053941-A2 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| CN-1092769-A | Cyclic urea derivatives, the method that contains the pharmaceutical composition of these compounds and prepare them | THOMAE GMBH DR K (DE) | 1994-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121300-A1 | METHOD OF FLUORINATION USING IODONIUM YLIDES | FLI1, ABL1, PFAS | NCF1 1987/4885AURKA 408/4885TTK 1780/4885 |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | NCF1 992/4885AURKA 3775/4885TTK 3152/4885 |
| US-10259800-B2 | Method of fluorination using iodonium ylides | FLI1, ABL1, PFAS | NCF1 1987/4885AURKA 408/4885TTK 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.